Aprea Therapeutics Inc.

04/08/2021 | Press release | Distributed by Public on 04/08/2021 11:48

Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)